Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 5/20 | 0.46 |
| ▸ | CLK2 | P49760 | 6/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.45 |
| ▸ | CLK3 | P49761 | 3/20 | 0.45 |
| ▸ | JAK2 | O60674 | 8/20 | 0.44 |
| ▸ | TYK2 | P29597 | 3/20 | 0.42 |
| ▸ | JAK3 | P52333 | 3/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.41 |
| ▸ | PLK4 | O00444 | 2/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.41 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | MARK3 | P27448 | 2/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.41 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30633398 | 1.00 | NUDT1 (0.46) | NUDT1CLK2DYRK1ACLK3JAK2 | |
| SCHEMBL31240758 | 0.90 | MMP13 (0.44) | NUDT1CLK2DYRK1ACLK3JAK2 | |
| SCHEMBL26685885 | 0.90 | MMP13 (0.49) | NUDT1CLK2DYRK1ACLK3JAK2 | |
| SCHEMBL31240624 | 0.90 | MMP13 (0.49) | NUDT1CLK2DYRK1ACLK3JAK2 | |
| SCHEMBL26685791 | 0.88 | NUDT1 (0.60) | NUDT1CLK2DYRK1ACLK3JAK2 | |
| SCHEMBL31420159 | 0.88 | NUDT1 (0.60) | NUDT1CLK2DYRK1ACLK3JAK2 | |
| SCHEMBL31240425 | 0.88 | NUDT1 (0.48) | NUDT1CLK2DYRK1ACLK3JAK2 | |
| SCHEMBL26686408 | 0.88 | NUDT1 (0.48) | NUDT1CLK2DYRK1ACLK3JAK2 | |
| SCHEMBL31240633 | 0.85 | CCNK (0.54) | NUDT1CLK2DYRK1ACLK3JAK2 | |
| SCHEMBL26686484 | 0.85 | CCNK (0.54) | NUDT1CLK2DYRK1ACLK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | claimed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | claimed |
| CN-119562945-A | IKK inhibitors | 癌症研究技术有限公司 | 2025-03-04 | — | — | CN | claimed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | claimed |
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-119562945-A | IKK inhibitors | 癌症研究技术有限公司 | 2025-03-04 | — | — | CN | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | NUDT1 3400/4885CLK2 1653/4885DYRK1A 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.